Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.
Rocío Díaz AcedoMercedes Galvan BanqueriEsther Márquez SaavedraPublished in: Journal of clinical pharmacy and therapeutics (2020)
The ITCs indicated no efficacy differences between anti-interleukin-17 drugs, except for secukinumab versus brodalumab 52-week analysis in terms of achieving PASI 100. All three drugs appear to act as equivalent clinical treatments for psoriasis. However, independent head-to-head trials should be carried out.